Lv1
50 积分 2025-04-08 加入
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
4小时前
待确认
Tumor Burden Monitoring with Circulating Tumor DNA During Treatment in Patients with Esophageal Squamous Cell Carcinoma
28天前
已完结
Tumor Burden Monitoring with Circulating Tumor DNA During Treatment in Patients with Esophageal Squamous Cell Carcinoma
1个月前
已完结
Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis
1个月前
已完结
High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial
2个月前
已完结
Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis
2个月前
已完结
P3.06D.02 Dynamic ctDNA-mrd Indicates Pathological Benefits of Additional Neoadjuvant Chemoimmunotherapy Courses for Locally Advanced NSCLC
2个月前
已关闭
Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trial
2个月前
已完结
Surgically Resectable Non-Small Cell Lung Cancer: A Contemporary Approach
2个月前
已完结
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
